Study of Eye Movements (EYE) as Early Markers of Brain Dysfunction (BRAIN) in Parkinson's Disease (PARK)

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04212637

Acronym

eyebrainpark

Enrollment

Registered

2019-12-27

Start date

2021-01-31

Completion date

2022-01-31

Last updated

2020-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Brief summary

Identify the neural bases of eye movements during visual tasks and their dysfunction at early stages of Parkinson disease (de novo).

Interventions

OTHERMRI

Examine BOLD activity in relation to eye movements measures

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

for all: * Visual acuity normal or corrected to normal * Affiliation to a social security scheme (copy of the vital card in support) * Signed informed consent * Medical examination according to the participation in the MRI examination * MMSE score\> 23/30 For Parkinson patient: * Diagnosis of Parkinson's disease * Presence of asymmetric bradykinesia and rest tremor and / or stiffness * Hoehn & Yahr Stadium I-II / V

Exclusion criteria

for all: * Unprotected Majors unable to express their consent * Protected Major (Persons mentioned in Articles L1121-5,6 and 8 of the public health code) * Significant hearing or motor impairment * Past or present neuropsychiatric pathology (except benign epilepsy) * Taking narcotics and / or drugs for neurocognitive purposes * Existence of a severe condition in general (cardiac, respiratory, hematological, renal, hepatic, cancerous) * Any other neurodegenerative pathology or treatment that may affect the oculomotor control For Parkinson patient: * Treatment for Parkinson's disease (except the inhibitors of monoaminoxidase B or MAO-B, such as selegiline and rasagiline).

Design outcomes

Primary

Measure	Time frame	Description
MRI images	1 hour	Functional and anatomical brain volumes

Secondary

Measure	Time frame	Description
Eye latency	1 hour	latency (milliseconds) of ocular saccades
eye amplitude	1 hour	amplitude (degree) of ocular saccades

Countries

France

Contacts

Primary ContactCarole PEYRIN, PhD

carole.peyrin@gmail.com(0)4 7682-5879

Backup ContactLouise KAUFFMANN

louise.kauffmann@gmail.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026